Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2014; 6(10): 752-758
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.752
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.752
Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib
Trevan D Fischer, Jin-Hee Wang, Adrian Vlada, Jae-Sung Kim, Kevin E Behrns, Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32610, United States
Author contributions: Fischer TD, Wang JH and Vlada A performed the majority of experiments; Kim JS and Behrns KE designed the study and wrote the manuscript in addition to providing financial support for this work.
Supported by In part by US National Institutes of Health, No. DK079879 (J-S Kim), DK090115 (J-S Kim), AG028740 (J-S Kim) and CA106493 (KE Behrns)
Correspondence to: Jae-Sung Kim, PhD, Department of Surgery, College of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, United States. jae.kim@surgery.ufl.edu
Telephone: +1-352-3927460 Fax: +1-352-3920080
Received: December 31, 2013
Revised: August 13, 2014
Accepted: September 6, 2014
Published online: October 27, 2014
Revised: August 13, 2014
Accepted: September 6, 2014
Published online: October 27, 2014
Core Tip
Core tip: Hepatocellular carcinoma (HCC) is difficult to treat. Sorafenib (SFN) is one treatment option. Autophagy has been proposed to play a pivotal role in HCC. In the present study we investigated the role of autophagy in SFN-treated HCC cells. We found that the autophagic responsiveness to SFN is markedly distinct between Hep3B and Huh7 cells.